నైరూప్య

OBSERVATIONAL STUDY ON SAFETY AND EFFICACY OF RIVAROXABAN IN COVID-19 AND POST COVID-19 PATIENTS

Sai Mouli Sistla, Mounika Chenna, Sireesha Pothani, Gummadi Laxmi Prasanna, Shashidar Reddy bommineni

Background: Rivaroxaban used to treat the coagulation is prescribed for covid 19 and post covid 19 (viral pneumonia and LRTI). To study the role of rivaroxaban in subjects with covid 19 and post covid 19 and assess the role of Rivaroxaban in covid 19 and post covid 19 subjects (LRTI or Viral pneumonia). To check the D DIMER value pre and post-giving Rivaroxaban. Methodology:A total of hundred subjects were taken between the age of eighteen to eighty years having increased d dimer in covid-19 and post covid-19 subjects. The subjects were prescribed rivaroxaban with the dose of 10 mg orally administered once a day. The d-dimer is checked prior to the drug administration and after taking rivaroxaban. Results:A rapid reduction in d-dimer values occurred from the administrating the drug. It is observed statistically that the rivaroxaban prescribed is safe and effective in managing coagulation of covid19 and post covid-19 subjects. Conclusion:This study confirms that the Rivaroxaban is desirable for subjects having coagulation during covid19 or post covid-19.